A Clinical Trial of Entinostat in Combination With Nivolumab for Patients With Previously Treated Unresectable or Metastatic Cholangiocarcinoma and Pancreatic Adenocarcinoma

Phase 2 Completed 44 enrolled Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Bristol-Myers Squibb · collab National Cancer Institute (NCI) · collab Syndax Pharmaceuticals · collab

Non-randomizedParallel-groupOpen-labelTreatment

Summary

The proposed study is an open-label, two-arm study of entinostat plus nivolumab in patients with unresectable or metastatic cholangiocarcinoma (CCA) or pancreatic ductal adenocarcinoma (PDAC).

Timeline

Start: 2017-11-06
Primary completion: 2020-11-20
Completion: 2020-11-20

Publications

Baretti M, Danilova L, Durham JN, Betts CB, Cope L, Sidiropoulos DN, Tandurella JA, Charmsaz S, Gross N, Hernandez A, Ho WJ, Thoburn C, Walker R, Leatherman J, Mitchell S, Christmas B, Saeed A, Gaykalova DA, Yegnasubramanian S, Fertig EJ, Coussens LM, Yarchoan M, Jaffee E, Azad NS. Entinostat in combination with nivolumab in metastatic pancreatic ductal adenocarcinoma: a phase 2 clinical trial. Nat Commun. 2024 Nov 12;15(1):9801. doi: 10.1038/s41467-024-52528-7.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Entinostat	Small molecule	5 mg	Oral
Subject	Nivolumab	Monoclonal antibody	240 mg	—

A Clinical Trial of Entinostat in Combination With Nivolumab for Patients With Previously Treated Unresectable or Metastatic Cholangiocarcinoma and Pancreatic Adenocarcinoma

Summary

Timeline

Publications

Drugs

Indications